Advanced search
Publication Cover
International Journal of Neuroscience Volume 119, 2009 - Issue 12
Submit an article Journal homepage
543
Views
82
CrossRef citations to date
0
Altmetric
Research Article

QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY

HUBERT H. FERNANDEZ Department of Neurology, College of Medicine University of Florida, USACorrespondence[email protected]
,
MICHAEL S. OKUN Department of Neurology, College of Medicine University of Florida, USA
,
RAMON L. RODRIGUEZ Department of Neurology, College of Medicine University of Florida, USA
,
IRENE A. MALATY Department of Neurology, College of Medicine University of Florida, USA
,
JANET ROMRELL Department of Neurology, College of Medicine University of Florida, USA
,
ANQI SUN Department of Epidemiology and Health Policy Research, University of Florida, USA
,
SAMUEL S. WU Department of Epidemiology and Health Policy Research, University of Florida, USA
,
SANDEEP PILLARISETTY Department of Neurology, College of Medicine University of Florida, USA
,
ANAND NYATHAPPA Department of Neurology, College of Medicine University of Florida, USA
&
STEPHAN EISENSCHENK Department of Neurology, College of Medicine University of Florida, USA
 show all
Pages 2196-2205 | Received 04 Jul 2009, Published online: 16 Nov 2009

Citations (82)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Stuart H Isaacson & Leslie Citrome. (2022) Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions. Expert Opinion on Drug Safety 21:7, pages 873-879.
Read now
Alice Powell, Elie Matar & Simon J. G. Lewis. (2022) Treating hallucinations in Parkinson’s disease. Expert Review of Neurotherapeutics 22:6, pages 455-468.
Read now
Celia Painous & Maria J Marti. (2020) Cognitive Impairment in Parkinson’s Disease: What We Know so Far. Research and Reviews in Parkinsonism 10, pages 7-17.
Read now
Han Zhang, Limin Wang, Yafei Fan, Lianhong Yang, Xiaojun Wen, Yunyun Liu & Zhonglin Liu. (2019) Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis. Neuropsychiatric Disease and Treatment 15, pages 2137-2149.
Read now
Kelly E. Lyons, Rajesh Pahwa, Neal Hermanowicz, Thomas Davis, Fernando Pagan & Stuart Isaacson. (2019) Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin. Expert Review of Clinical Pharmacology 12:7, pages 681-691.
Read now
Ines Chendo & Joaquim J Ferreira. (2016) Pimavanserin for the treatment of Parkinson’s disease psychosis. Expert Opinion on Pharmacotherapy 17:15, pages 2115-2124.
Read now
Umer Akbar & Joseph H Friedman. (2015) Recognition and treatment of neuropsychiatric disturbances in Parkinson’s disease. Expert Review of Neurotherapeutics 15:9, pages 1053-1065.
Read now
Leora L Borek & Joseph H Friedman. (2014) Treating psychosis in movement disorder patients: a review. Expert Opinion on Pharmacotherapy 15:11, pages 1553-1564.
Read now
David J Pedrosa & Lars Timmermann. (2013) Review: management of Parkinson’s disease. Neuropsychiatric Disease and Treatment 9, pages 321-340.
Read now
Joseph H Friedman. (2013) Pimavanserin for the treatment of Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy 14:14, pages 1969-1975.
Read now
Jennifer G Goldman, Christina L Vaughan & Christopher G Goetz. (2011) An update expert opinion on management and research strategies in Parkinson's disease psychosis. Expert Opinion on Pharmacotherapy 12:13, pages 2009-2024.
Read now

Articles from other publishers (71)

Fang Wang, Lulin Dai, Yixin Pan, Peng Huang, Chencheng Zhang, Bomin Sun & Dianyou Li. (2024) Unilateral anterior capsulotomy combined with deep brain stimulation for Parkinson's disease psychosis and motor dysfunctions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 128, pages 110865.
Crossref
Ismaeel Yunusa, Nazia Rashid, Roxanna Seyedin, Deepika Paratane & Krithika Rajagopalan. (2023) Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson’s Disease Psychosis: Systematic Review and Network Meta-Analysis. Journal of Geriatric Psychiatry and Neurology 36:5, pages 417-432.
Crossref
Oliver Phillips, Debolina Ghosh & Hubert H. Fernandez. (2023) Parkinson Disease Dementia Management: an Update of Current Evidence and Future Directions. Current Treatment Options in Neurology 25:5, pages 93-119.
Crossref
Fulvio Lauretani, Crescenzo Testa, Marco Salvi, Irene Zucchini, Francesco Giallauria & Marcello Maggio. (2023) Clinical Evaluation of Sleep Disorders in Parkinson’s Disease. Brain Sciences 13:4, pages 609.
Crossref
Brian J. Miller, Joseph P. McEvoy & William V. McCall. (2023) Meta-analysis of clozapine and insomnia in schizophrenia. Schizophrenia Research 252, pages 208-215.
Crossref
Shuo Zhang & Yan Ma. (2022) Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms. World Journal of Psychiatry 12:9, pages 1127-1140.
Crossref
Yuki Asahara, Taiji Mukai, Machiko Suda & Masahiko Suzuki. 2022. Dementia in Parkinson’s Disease - Everything you Need to Know. Dementia in Parkinson’s Disease - Everything you Need to Know.
Camila Aquino. 2022. Non-Motor Parkinson's Disease. Non-Motor Parkinson's Disease 212 223 .
Nazia Rashid, Andrew Shim, Sherry Andes, Sonja Quale & Victor Abler. (2021) Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson’s Disease Psychosis. Journal of Applied Gerontology 41:1, pages 198-206.
Crossref
Javier Vilches Vázquez & Jose Manuel Gallego Rodríguez. (2022) Cariprazina como alternativa farmacológica en el tratamiento de la psicosis en la enfermedad de Parkinson. Psiquiatría Biológica 29:1, pages 100347.
Crossref
Elaheh Akbarzadeh. 2022. Benzodiazepine-Based Drug Discovery. Benzodiazepine-Based Drug Discovery 295 320 .
Cynthia Kwan, Imane Frouni & Philippe Huot. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 4231 4269 .
Khashayar Dashtipour, Fiona Gupta, Robert A. Hauser, Cherian A. Karunapuzha & John C. Morgan. (2021) Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice. Parkinson's Disease 2021, pages 1-10.
Crossref
Cynthia Kwan, Imane Frouni & Philippe Huot. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 39 .
Andrew Ford & Osvaldo P. Almeida. (2020) Effect of biological treatments on psychotic symptoms in lewy body disease: A systematic review and meta‐analysis of randomized controlled trials . International Journal of Geriatric Psychiatry 35:10, pages 1083-1096.
Crossref
Ryo Iketani, Daisuke Furushima, Shinobu Imai & Hiroshi Yamada. (2020) Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis. Parkinsonism & Related Disorders 78, pages 82-90.
Crossref
Kevin Kyle & Jeff M. Bronstein. (2020) Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. Parkinsonism & Related Disorders 75, pages 55-62.
Crossref
John O'Brien, John Paul Taylor, Clive Ballard, Roger A Barker, Clare Bradley, Alistair Burns, Daniel Collerton, Sonali Dave, Rob Dudley, Paul Francis, Andrea Gibbons, Kate Harris, Vanessa Lawrence, Iracema Leroi, Ian McKeith, Michel Michaelides, Chaitali Naik, Claire O'Callaghan, Kirsty Olsen, Marco Onofrj, Rebecca Pinto, Gregor Russell, Peter Swann, Alan Thomas, Prabitha Urwyler, Rimona Sharon Weil & Dominic ffytche. (2020) Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. Journal of Neurology, Neurosurgery & Psychiatry 91:5, pages 512-519.
Crossref
Lei Mou, Wei Ding & Pedro Fernandez-Funez. (2020) Open questions on the nature of Parkinson’s disease: from triggers to spreading pathology. Journal of Medical Genetics 57:2, pages 73-81.
Crossref
Jack J. ChenHenry HuaLilian MassihiIvan PortilloAzita AlipourWilliam OndoKhashayar Dashtipour. (2019) Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. The Journal of Neuropsychiatry and Clinical Neurosciences 31:3, pages 188-195.
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clozapine Handbook. The Clozapine Handbook 10 43 .
Peter Brock, James M Fisher, Annette Hand & Richard W Walker. (2019) Highlighting the goals for Parkinson’s care: commentary on NICE Guidelines for Parkinson’s in Adults (NG71). Age and Ageing 48:3, pages 323-326.
Crossref
Wissam Deeb, Kamilia Nozile-Firth & Michael S. Okun. 2019. Geriatric Neurology. Geriatric Neurology 257 277 .
Kevin J. Black, Henry Nasrallah, Stuart Isaacson, Mark Stacy, Rajesh Pahwa, Charles H. Adler, Gustavo Alva, Jeffrey W. Cooney, Daniel Kremens, Matthew A. Menza, Jonathan M. Meyer, Ashwin A. Patkar, Tanya Simuni, Debbi A. Morrissette & Stephen M. Stahl. (2018) Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus. CNS Spectrums 23:6, pages 402-413.
Crossref
Leslie Citrome, James C. Norton, Kathy Chi-Burris & George Demos. (2017) Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums 23:3, pages 228-238.
Crossref
Shyam C. Panchal & William G. Ondo. (2018) Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis. Current Psychiatry Reports 20:1.
Crossref
Ruth B Schneider, Julia Iourinets & Irene H Richard. (2017) Parkinson's disease psychosis: presentation, diagnosis and management. Neurodegenerative Disease Management 7:6, pages 365-376.
Crossref
Annemarie Unger, Thomas Foki & Gabriele Sachs. (2017) Einsatz von Antipsychotika bei Parkinson-Psychose und MultimorbiditätUse of antipsychotics in the therapy of Parkinson’s psychosis and multimorbidity. psychopraxis. neuropraxis 20:5, pages 203-207.
Crossref
Kyle John Wilby, Eric G. Johnson, Hannah E. Johnson & Mary H. H. Ensom. (2017) Evidence-Based Review of Pharmacotherapy Used for Parkinson’s Disease Psychosis. Annals of Pharmacotherapy 51:8, pages 682-695.
Crossref
Amy W. Amara, Lana M. Chahine & Aleksandar Videnovic. (2017) Treatment of Sleep Dysfunction in Parkinson’s Disease. Current Treatment Options in Neurology 19:7.
Crossref
Katrin Rauen & Steffi Weidt. (2017) Insomnie – ein Symptom mit multifaktorieller Genese. Praxis 106:13, pages 715-721.
Crossref
X. Garcia & H.H. Fernandez. 2017. Reference Module in Neuroscience and Biobehavioral Psychology. Reference Module in Neuroscience and Biobehavioral Psychology.
. (2016) Manage psychosis in Parkinson’s disease using a stepwise approach. Drugs & Therapy Perspectives 33:1, pages 16-21.
Crossref
Harini Sarva & Claire Henchcliffe. (2016) Evidence for the use of pimavanserin in the treatment of Parkinson’s disease psychosis. Therapeutic Advances in Neurological Disorders 9:6, pages 462-473.
Crossref
Oluwadamilola O. Ojo & Hubert H. Fernandez. (2016) Current Understanding of Psychosis in Parkinson’s Disease. Current Psychiatry Reports 18:10.
Crossref
Sara Garcia-Ptacek & Milica G. Kramberger. (2016) Parkinson Disease and Dementia. Journal of Geriatric Psychiatry and Neurology 29:5, pages 261-270.
Crossref
Daniel Martinez-Ramirez, Michael S Okun & Michael S Jaffee. (2016) Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists. Neurodegenerative Disease Management 6:4, pages 319-330.
Crossref
Philippe Desmarais, Fadi Massoud, Josée Filion, Quoc Dinh Nguyen & Paulina Bajsarowicz. (2016) Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders. Journal of Geriatric Psychiatry and Neurology 29:4, pages 227-236.
Crossref
Anna Chang & Susan H. Fox. (2016) Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management. Drugs 76:11, pages 1093-1118.
Crossref
Jeffrey W. Cooney & Mark Stacy. (2016) Neuropsychiatric Issues in Parkinson’s Disease. Current Neurology and Neuroscience Reports 16:5.
Crossref
Massimiliano Buoli, Alice Caldiroli & Alfredo Carlo Altamura. (2015) Psychiatric Conditions in Parkinson Disease. Journal of Geriatric Psychiatry and Neurology 29:2, pages 72-91.
Crossref
Nevena Divac, Radan Stojanović, Katarina Savić Vujović, Branislava Medić, Aleksandar Damjanović & Milica Prostran. (2016) The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease. Behavioural Neurology 2016, pages 1-6.
Crossref
Ketan Dipak Jethwa & Oluwademilade A. Onalaja. (2018) Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis. BJPsych Open 1:1, pages 27-33.
Crossref
Unax Lertxundi, Arantxazu Isla Ruiz, María Ángeles Solinís Aspiazu, Saioa Domingo-Echaburu, Montserrat García, Carmelo Aguirre & Juan Carlos García-Moncó. (2015) Adverse Reactions to Antipsychotics in Parkinson Disease. Clinical Neuropharmacology 38:3, pages 69-84.
Crossref
Elaine Perry, Urs Peter Mosimann & Daniel Collerton. 2015. The Neuroscience of Visual Hallucinations. The Neuroscience of Visual Hallucinations 321 341 .
Başar Bilgiç, Haşmet A. Hanağası & Murat Emre. 2015. Neuropsychiatric Symptoms of Movement Disorders. Neuropsychiatric Symptoms of Movement Disorders 53 77 .
Scott J. Kutscher, Siavash Farshidpanah & Daniel O. Claassen. (2014) Sleep Dysfunction and its Management in Parkinson’s Disease. Current Treatment Options in Neurology 16:8.
Crossref
Murat Emre, Paul J. Ford, Başar Bilgiç & Ergun Y. Uç. (2014) Cognitive impairment and dementia in Parkinson's disease: Practical issues and management. Movement Disorders 29:5, pages 663-672.
Crossref
Jennifer G. Goldman & Samantha Holden. (2014) Treatment of Psychosis and Dementia in Parkinson’s Disease. Current Treatment Options in Neurology 16:3.
Crossref
Jeffrey Cummings, Stuart Isaacson, Roger Mills, Hilde Williams, Kathy Chi-Burris, Anne Corbett, Rohit Dhall & Clive Ballard. (2014) Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. The Lancet 383:9916, pages 533-540.
Crossref
Barbara Connolly & Susan H. Fox. (2013) Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease. Neurotherapeutics 11:1, pages 78-91.
Crossref
Thomas Knuijver, Indira Tendolkar, Rianne Esselink & Philip van Eijndhoven. (2013) Parkinson-psychose: een complex samenspel van ziekte- en medicatie-gerelateerde factoren. Tijdschrift voor Neuropsychiatrie en Gedragsneurologie 1:2, pages 45-50.
Crossref
ROSA QUELHAS. (2013) Psychiatric Care in Parkinson’s Disease. Journal of Psychiatric Practice 19:2, pages 118-141.
Crossref
David Salat & Eduardo Tolosa. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease 389 413 .
Thien Thien Lim, Kelvin L. Chou & Hubert H. Fernandez. 2013. Handbook of Parkinson’s Disease. Handbook of Parkinson’s Disease 192 224 .
Michelle J Nichols, Johanna M Hartlein, Meredith GA Eicken, Brad A Racette & Kevin J Black. (2013) A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000Research 2, pages 150.
Crossref
Yoshikuni Mizuno. (2012) An update on the management of juvenile and young-onset Parkinson’s disease. Future Neurology 7:5, pages 581-593.
Crossref
Arvid Rongve, Eirik Auning, Uwe Ehrt & Dag Årsland. (2012) Psykose ved Parkinsons sykdom. Tidsskrift for Den norske legeforening 132:2, pages 155-158.
Crossref
Iris E. C. Sommer & Jan Dirk Blom. 2012. Hallucinations. Hallucinations 331 347 .
Joseph H. Friedman. (2011) Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease. Journal of Pharmacy Practice 24:6, pages 534-540.
Crossref
Philippe Huot, Susan H. Fox & Jonathan M. Brotchie. (2011) The serotonergic system in Parkinson's disease. Progress in Neurobiology 95:2, pages 163-212.
Crossref
Klaus Seppi, Daniel Weintraub, Miguel Coelho, Santiago Perez-Lloret, Susan H. Fox, Regina Katzenschlager, Eva-Maria Hametner, Werner Poewe, Olivier Rascol, Christopher G. Goetz & Cristina Sampaio. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders 26:S3, pages S42-S80.
Crossref
Chie Usui, Kotaro Hatta, Nagafumi Doi, Shinichiro Kubo, Rie Kamigaichi, Atsushi Nakanishi, Hiroyuki Nakamura, Nobutaka Hattori & Heii Arai. (2011) Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:7, pages 1704-1708.
Crossref
George Zhong, Sharon Linda Naismith, Naomi Louise Rogers & Simon John Geoffrey Lewis. (2011) Sleep–wake disturbances in common neurodegenerative diseases: A closer look at selected aspects of the neural circuitry. Journal of the Neurological Sciences 307:1-2, pages 9-14.
Crossref
Joseph H Friedman. (2011) Managing psychosis in Parkinson’s disease. Neurodegenerative Disease Management 1:3, pages 217-226.
Crossref
Michael J. Aminoff, Chad W. Christine, Joseph H. Friedman, Kelvin L. Chou, Kelly E. Lyons, Rajesh Pahwa, Bastian R. Bloem, Sotirios A. Parashos, Catherine C. Price, Irene A. Malaty, Robert Iansek, Ivan Bodis-Wollner, Oksana Suchowersky, Wolfgang H. Oertel, Jorge Zamudio, Joyce Oberdorf, Peter Schmidt & Michael S. Okun. (2011) Management of the hospitalized patient with Parkinson’s disease: Current state of the field and need for guidelines. Parkinsonism & Related Disorders 17:3, pages 139-145.
Crossref
Dag AarslandUwe Ehrt & Irena Rektorova. (2011) Cognitive and psychiatric disturbances in Parkinson’s disease. Aging Health 7:1, pages 123-142.
Crossref
Jennifer G. Goldman. (2011) New Thoughts on Thought Disorders in Parkinson's Disease: Review of Current Research Strategies and Challenges. Parkinson's Disease 2011, pages 1-12.
Crossref
Paul Shotbolt, Mike Samuel & Anthony David. (2010) Quetiapine in the treatment of psychosis in Parkinson’s disease. Therapeutic Advances in Neurological Disorders 3:6, pages 339-350.
Crossref
Joseph H. Friedman. (2010) Parkinson’s disease psychosis 2010: A review article. Parkinsonism & Related Disorders 16:9, pages 553-560.
Crossref
Laura B. Zahodne & Hubert H. Fernandez. (2010) Parkinson’s Psychosis. Current Treatment Options in Neurology 12:3, pages 200-211.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.